Citations

Key Points A continued monoclonal protein response after ASCT in the absence of further therapy is prognostic in MM patients.

The use of dual-energy computed tomography (DECT) for evaluating urinary calculi has been appreciated due to the modality’s capability of differentiating between uric acid (UA) and non-UA stones, which are color coded based on a postprocessing algorithm. No other imaging modality or laboratory test is able to identify the stone composition without first attaining the stone material. Knowledge of the stone composition is clinically significant since UA calculi may be treated medically whereas non-UA calculi may require surgical removal. Regardless of the stone type, ureteral stents are often placed to prevent or treat obstruction. Recent work has demonstrated that commonly used stents are also colored based on their dual energy characteristics and may thereby either improve or obscure the identification of adjacent calculi. Herein, we report the case of a 65-year-old man who underwent percutaneous nephrolithotomy of a large staghorn stone with subsequent significant residual stone fragments noted on a follow-up scan. By using three-dimensional DECT and taking advantage of color contrasting, the stone composition, burden, shape, and boundary were clearly depicted apart from the adjacent stent, resulting in successful medical treatment and obviating the need for further surgical intervention.

According to recent statistics from the American Heart Association, Heart Failure (HF) affects 5.7 million Americans [1]. HF is characterized by the global dilation of the heart, which leads to an increase in ventricular volume and a reduction in pumping efficiency. Several treatment strategies have been investigated to combat the adverse remodeling that leads to the progression of HF [2,3]. These therapies include reshaping the heart by means of surgical intervention and implantation of medical devices.

An intracranial aneurysm (IA) is a pathological condition of cerebral arteries characterized by local enlargements of the arterial wall, typically into a saccular shape. Rupture of the aneurysm sac can result in devastating cerebral hemorrhage. Hemodynamic factors are believed to play an important role in initiation, development and rupture of IAs [1–3]. However, the coupling between hemodynamics and aneurysm pathophysiology is complex and remains poorly understood. Patient specific diagnostics regarding risk of rupture can be substantially advanced by improving our understanding of the in-vivo response of the aneurysm wall to intra-saccular hemodynamic stresses. A mechanism for fundamental studies of the impact of chronically altered WSS on the intact vascular wall is provided by animal models. However, cerebral aneurysms have not been shown to occur naturally in animals. Thus, a number of animal models have been created for studying aneurysm pathogenesis including those in mice, rats, rabbits, canines, swine and primates. To make meaningful use of these models, it is important to evaluate their relevance to human biomechanics and pathophysiology.

Tendons and ligaments are soft connective tissues that play an important role in the musculoskeletal system. The tendon transmits the concentrated tensions generated by the muscle to the bone, and the ligaments stabilize and guide the movement between bones connected at the articulating joints. To perform these tasks, these soft connective tissues are uniquely built to bear load transmission, but are flexible enough to allow the changing direction in their paths of alignment. To accomplish these requirements, the tendons and ligaments have a hierarchy of highly aligned collagen structures consisting of fibrils, fascicles and fibers, along with the ground substance of proteoglycans and glycolipids to form the tendon and ligament tissues.

BackgroundVancomycin treatment failure has been associated with low serum vancomycin trough concentrations, prompting recommendations to increase the daily doses in adults and children. Despite more aggressive vancomycin dosing, there continues to be significant variability in vancomycin trough concentrations in pediatric patients.MethodsTo determine if vancomycin trough concentrations in pediatric patients differ by age and weight, we reviewed records of hospitalized patients who received vancomycin between 2008 and 2012. Patients were divided into groups that received vancomycin 40 mg/kg/day (2008–2009) or 60 mg/kg/day (2010–2012). Vancomycin trough concentrations were compared between groups and within the 60 mg/kg/day group, stratified by patient age and weight.ResultsAfter increasing the vancomycin dose from 40 to 60 mg/kg/day, initial trough concentrations increased significantly in patients younger than 2 and greater than 6 years of age, but not in patients between the ages of 2 and 5 years. In the 60 mg/kg/day group, only 16.7% of patients between 2 and 5 years of age had initial trough concentrations in the therapeutic range (10–20 μg/ml). Initial trough concentrations were therapeutic in a greater proportion of patients ages 6–12 years (38.7%) and 13–18 years (63.0%). Patients between the ages of 13 and 18 had the highest proportion of supratherapeutic initial vancomycin trough concentrations (14.8%). Patients weighing over 50 kg had significantly higher trough concentrations than patients 50 kg or less (17.1 μg/ml vs 9.3 μg/ml, p<0.001).ConclusionAlthough increasing the vancomycin dose from 40 to 60 mg/kg/day led to a significant increase in vancomycin trough concentrations, a large proportion of patients receiving 60 mg/kg/day of vancomycin had trough concentrations outside of the therapeutic range. Specifically, patients younger than 6 years tended to have low trough concentrations, whereas adolescents and children over 50 kg were more likely to have elevated trough concentrations. Vancomycin dosing strategies in pediatric patients should consider age and weight as well as renal function and indication.

The androgen receptor (AR) is important in the development of the prostate by regulating transcription, cellular proliferation, and apoptosis. AR undergoes posttranslational modifications that alter its transcription activity, translocation to the nucleus and stability. The posttranslational modifications that regulate these events are of utmost importance to understand the functional role of AR and its activity. The majority of these modifications occur in the activation function-1 (AF1) region of the AR, which contains the transcriptional activation unit 1 (TAU1) and 5 (TAU5). Identification of the modifications that occur to these regions may increase our understanding of AR activation in prostate cancer and the role of AR in the progression from androgen-dependent to castration-resistant prostate cancer (CRPC). Most of the posttranslational modifications identified to date have been determined using the full-length AR in androgen dependent cells. Further investigations into the role of posttranslational modifications in androgen-independent activation of full-length AR and constitutively active splicing variants are warranted, findings from which may provide new therapeutic options for CRPC.